This result is in agreement with the findings of Xiao et al. who showed that manipulation of tryptophan metabolism by an IDO1 inhibitor leads to a marked decline in proinflammatory cytokines, indicating its therapeutic potential in controlling CRS in SARS-CoV-2 infection30. Here, IDO1 is linked to congenital rubella syndrome.